Sen. Mike Braun

This bill requires the Department of the Treasury to instruct the U.S. executive directors at certain multilateral development banks, such as the Asian Development Bank, to oppose providing a loan, financial assistance, or technical assistance to China. The executive directors must also advocate and vote to end lending and assistance to a country that has exceeded certain income thresholds.

This resolution expresses the condolences of the Senate regarding the death of the Honorable Carl Levin, former Senator for Michigan.

This resolution expresses the condolences of the Senate regarding the death of the Honorable Mike Enzi, former Senator for Wyoming.

Protecting Students From Racial Hostility Act This bill prohibits school curriculums or teachings that promote certain concepts based on race. Specifically, the bill prohibits schools from promoting concepts that result in a racially hostile environment , which the bill defines as an environment in which (1) racial discrimination has created an adverse setting, (2) an individual is fearful due to a racially intimidating or offensive environment, or (3) an individual is restricted from participating in or benefiting from a program or activity on the basis of race. Prohibited concepts include the idea that (1) one race is inherently superior to another, (2) the United States is fundamentally racist, and (3) an individual bears responsibility for the past actions of others of the same race. The bill makes the use of such curriculums or teachings a violation of Title VI of the Civil Rights Act of 1964, which prohibits discrimination based on race, color, or national origin in federally funded programs or activities. Any intimidation, threat, or other interference with respect to an individual's rights or participation in related proceedings (e.g., the ability to file complaints about the use of prohibited curriculums) shall also be considered a violation of Title VI. The bill applies to elementary and secondary schools and to colleges and universities.

Fiscal State of the Nation Resolution This concurrent resolution requires the congressional budget committees to conduct an annual joint hearing to receive a presentation from the Comptroller General regarding (1) the Government Accountability Office's audit of the financial statement of the executive branch, and (2) the financial position and condition of the federal government.

Intergenerational Financial Obligations Reform Act This bill requires the Congressional Budget Office, the Office of Management and Budget, and the Government Accountability Office to provide various reports that include a fiscal gap analysis and a generational accounting analysis. Under the bill, the fiscal gap generally refers to the sum of (1) the total amount of Treasury liabilities outstanding on the last day of the budget year, and (2) the discounted present value of the projected difference between federal spending and revenues during the period of the budget year and at least the next 75 fiscal years (excluding spending for net interest and principal payments on Treasury liabilities). A generational accounting analysis addresses the fiscal impact that projected federal spending and tax burdens will have on various generations of individuals.

This bill requires the President to report to Congress on the national security risks associated with any plans by China's government to create an official digital currency.

Restore Public Health Institution Trust Act of 2021 This bill requires the Government Accountability Office to report on public health messaging and other recommendations of the Centers for Disease Control and Prevention (CDC). The report must specifically address (1) the data used to make recommendations, (2) the effect of inconsistent messaging on the public's trust in the CDC and willingness to follow its vaccine and other COVID-19 guidance, and (3) the degree to which outside entities influenced CDC recommendations.

Affordable Prescriptions for Patients Act of 2021 This bill prohibits product hopping by drug manufacturers, authorizes the Federal Trade Commission to enforce this prohibition, and imposes limits on patent litigation involving biological products. Generally, product-hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a follow-on product is a modified version of the reference drug that shares an indication (what the drug is used for) with the reference drug. The bill presumes product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration (FDA) has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product. A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition. The bill also limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get FDA market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.

Prescription Pricing for the People Act of 20 21 This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs. The FTC also must provide recommendations to increase transparency in the supply chain and prevent anticompetitive practices.